Observation of the Impact of Hypoxia - Inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500106730

Enrollment

Unknown

Registered

2025-07-29

Start date

2025-08-01

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

1:Roxadustat

2:Erythropoietin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 80 years old, with maintenance hemodialysis for at least 3 months; patients have both renal anemia and sarcopenia simultaneously. The diagnostic criteria for renal anemia are Hb 70 - 100 g/L and eGFR < 15 mL/min/1.73m^2.

Exclusion criteria

Exclusion criteria: Active infection (CRP > 20 mg/L) Malignant tumor History of ESA resistance (Hb 300 IU/kg/week) Laboratory abnormalities: Iron overload (SF > 800 µg/L or TSAT > 50%) Hyperkalemia (serum potassium > 5.5 mmol/L before dialysis) Special contraindications: Pregnancy, planned kidney transplantation, severe liver dysfunction (Child-Pugh C), use of androgens or immunosuppressants within 3 months

Design outcomes

Primary

Measure	Time frame
hemoglobin;Muscle mass;	—

Countries

China

Contacts

Public ContactJunya Jia

Department of Nephrology, Tianjin Medical University General Hospital

jiajunya@126.com+86 138 2173 5536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026